DNA methylation at the novel CpG sites in the promoter of MED15/PCQAP gene as a biomarker for head and neck cancers

Biomarker Insights

Volumn 9, Issue , 2014, Pages 53-60

  Ovchinnikov, Dmitry A ^a   Wan, Yunxia ^a   Coman, William B ^a   Pandit, Pratibala ^a   Cooper White, Justin J ^a   Herman, James G ^b   Punyadeera, Chamindie ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

Diagnostics; DNA methylation; Non invasiveness; Saliva

Indexed keywords

DINUCLEOTIDE; TUMOR MARKER;

ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CPG ISLAND; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DNA METHYLATION; EPIGENETICS; GENE; GENETIC REGULATION; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; HUMAN TISSUE; MED15 PCQAP GENE; PAPILLOMAVIRUS INFECTION; POLYMERASE CHAIN REACTION; PREDICTIVE VALUE; PROMOTER REGION; RECEIVER OPERATING CHARACTERISTIC; SALIVA ANALYSIS; SENSITIVITY AND SPECIFICITY; SMOKING;

EID: 84903985832     PISSN: None     EISSN: 11772719     Source Type: Journal    
DOI: 10.4137/BMIMI.S16199     Document Type: Article

References (24)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin. 2005; 55: 74-108.
2. Boyle P, Levin B. World Cancer Report. 2008: 510. http: //www.iarc.fr/en/publications/pdfs-online/wcr/2008/wcr_2008.pdf.
3. Sankaranarayanan R, Masuyer E, Swaminathan R, Ferlay J, Whelan S. Head and neck cancer: a global perspective on epidemiology and prognosis. Anticancer Res. 1998; 18: 4779-86.
4. Thomas SJ, Bain CJ, Battistutta D, Ness AR, Paissat D, Maclennan R. Betel quid not containing tobacco and oral cancer: a report on a case-control study in Papua New Guinea and a meta-analysis of current evidence. Int J Cancer. 2007; 120: 1318-23.
5. Mohamed R, Campbell JL, Cooper-White J, Dimeski G, Punyadeera C. The impact of saliva collection and processing methods on CRP, IgE, and myoglobin immunoassays. Clin Transl Med. 2013; 1: 19.
6. Pandit P, Cooper-White J, Punyadeera C. High-yield RNA-extraction method for saliva. Clin Chem. 2013 Jul; 59(7): 1118-22.
7. Pfaffe T, Cooper-White J, Beyerlein P, Kostner K, Punyadeera C. Diagnostic potential of saliva: current state and future applications. Clin Chem. 2011; 57: 675-87.
8. Punyadeera C. Human saliva as a tool to investigate intimate partner violence. Brain Behav Immun. 2012; 26: 541-2.
9. Schulz BL, Cooper-White J, Punyadeera CK. Saliva proteome research: current status and future outlook. Crit Rev Biotechnol. 2013 Sep; 33(3): 246-59.
10. Topkas E, Keith P, Dimeski G, Cooper-White J, Punyadeera C. Evaluation of saliva collection devices for the analysis of proteins. Clin Chim Acta. 2012; 413: 1066-70.
11. Ovchinnikov DA, Cooper MA, Pandit P, etal. Tumor-suppressor gene promoter hypermethylation in saliva of head and neck cancer patients. Transl Oncol. 2012; 5: 321-6.
12. Righini CA, de Fraipont F, Timsit JF, etal. Tumor-specific methylation in saliva: a promising biomarker for early detection of head and neck cancer recurrence. Clin Cancer Res. 2007; 13: 1179-85.
13. Zhao M, Yang X, Fu Y, etal. Mediator MED15modulates transforming growth factor beta (TGFbeta)/Smad signaling and breast cancer cell metastasis. J Mol Cell Biol. 2012; 5: 57-60.
14. Imielinski M, Berger AH, Hammerman PS, etal. Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing. Cell. 2012; 150: 1107-20.
15. Worsham MJ, Chen KM, Stephen JK, Havard S, Benninger MS. Novel approaches to global mining of aberrantly methylated promoter sites in squamous head and neck cancer. Otolaryngol Head Neck Surg. 2010; 143: 116-21.
16. Ongenaert M, Van Neste L, De Meyer T, Menschaert G, Bekaert S, Van Criekinge W. PubMeth: a cancer methylation database combining text-mining and expert annotation. Nucleic Acids Res. 2008; 36: D842-6.
17. Zou KH, O'Malley AJ, Mauri L. Receiver-operating characteristic analysis for evaluating diagnostic tests and predictive models. Circulation. 2007; 115: 654-7.
18. Wands AM, Wang N, Lum JK, Hsieh J, Fierke CA, Mapp AK. Transient-state kinetic analysis of transcriptional activator. DNA complexes interacting with a key coactivator. J Biol Chem. 2011; 286: 16238-45.
19. Rosenbaum E, Hoque MO, Cohen Y, etal. Promoter hypermethylation as an independent prognostic factor for relapse in patients with prostate cancer following radical prostatectomy. Clin Cancer Res. 2005; 11: 8321-5.
20. Roupelieva M, Griffiths SJ, Kremmer E, etal. Kaposi's sarcoma-associated herpesvirus Lana-1 is a major activator of the serum response element and mitogen-activated protein kinase pathways via interactions with the Mediator complex. J Gen Virol. 2010; 91: 1138-49.
21. Roh JL, Wang XV, Manola J, Sidransky D, Forastiere AA, Koch WM. Clinical correlates of promoter hypermethylation of four target genes in head and neck cancer: a cooperative group correlative study. Clin Cancer Res. 2013; 19: 2528-40.
22. Schussel J, Zhou XC, Zhang Z, etal. EDNRB and DCC salivary rinse hypermethylation has a similar performance as expert clinical examination in discrimination of oral cancer/dysplasia versus benign lesions. Clin Cancer Res. 2013; 19: 3268-75.
23. Scully C, Field JK, Tanzawa H. Genetic aberrations in oral or head and neck squamous cell carcinoma (SCCHN): 1. Carcinogen metabolism, DNA repair and cell cycle control. Oral Oncol. 2000; 36: 256-63.
24. Pai SI, Westra WH. Molecular pathology of head and neck cancer: implications for diagnosis, prognosis, and treatment. Annu Rev Pathol. 2009; 4: 49-70.